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Abstract
Objective: To determine the variation of IFN-c and IL-17 responses to M. tuberculosis antigens in healthy TST+ humans.
Methods: We isolated peripheral blood mononuclear cells from 21 TST+ healthy adults, stimulated them with
phytohemagglutinin (PHA), PPD, Ag85B, ESAT-6, and live M. bovis BCG, and assayed IFN-c and IL-17 secretion by ELISA
in supernatants after 24 or 72 hours of incubation respectively.
Results: As in other studies, we found a wide range of IFN-c responses to M. tuberculosis antigens; the variation significantly
exceeded that observed in the same donors to the polyclonal T cell stimulus, phytohemagglutinin (PHA). In addition, we
assayed IL-17 secretion in response to the same stimuli, and found less subject-to-subject variation. Analysis of the ratio of
IFN-c to IL-17 secretion on a subject-to-subject basis also revealed a wide range, with the majority of results distributed in a
narrow range, and a minority with extreme results all of which were greater than that in the majority of subjects. The data
suggest that study of exceptional responses to M. tuberculosis antigens may reveal immunologic correlates with specific
outcomes of M. tuberculosis infection.
Conclusion: Variation of IFNc and IFN-c/IL-17 responses to mycobacterial antigens exceeds that of responses to the
polyclonal stimulus, PHA, in TST positive healthy humans. This indicates a quantitative spectrum of human immune
responses to infection with M. tuberculosis. Since the outcome of human infection with M. tuberculosis varies greatly,
systematic study of multiple immune responses to multiple antigens is likely to reveal correlations between selected
immune responses and the outcomes of infection.
Citation: Fan L, Xiao H-p, Hu Z-y, Ernst JD (2012) Variation of Mycobacterium tuberculosis Antigen-Specific IFN-c and IL-17 Responses in Healthy Tuberculin Skin
Test (TST)-Positive Human Subjects. PLoS ONE 7(8): e42716. doi:10.1371/journal.pone.0042716
Editor: Delia Goletti, National Institute for Infectious Diseases (L. Spallanzani), Italy
Received March 20, 2012; Accepted July 10, 2012; Published August 6, 2012
Copyright:  2012 Fan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by NIH grants R01 AI090928 and NIH/NCRR 1UL1RR029893-0109. The funder had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: shhuzy@163.com (ZH); joel.ernst@med.nyu.edu (JE)
Introduction
Tuberculosis is one of the leading infectious diseases in the
world; the estimated total number of incident cases of tuberculosis
worldwide rose to 9.4 million in 2009—more than at any other
time in history, resulting in an estimated 1.7 million deaths each
year [1]. Mycobacterium tuberculosis can establish lifelong persistent
infection in immunocompetent hosts, reflecting a remarkable
adaptation to its human hosts. Despite the inability of adaptive
immune responses to eradicate M. tuberculosis, CD4 T cells play a
major role in controlling M. tuberculosis infection in humans, as
indicated by the observations that HIV-infected, CD4 T cell-
deficient individuals are more susceptible to tuberculosis than are
HIV-uninfected individuals. Moreover, the incidence of active
tuberculosis in HIV-infected individuals is inversely proportion to
the number of CD4 T cells in peripheral blood [2,3].
In addition to their roles in providing protective immunity
against tuberculosis, M. tuberculosis antigen-specific CD4 T cells
may also contribute to immunopathology in the lungs and other
organs [4,5]. For example, multiple studies have revealed that, in
HIV-infected patients with active tuberculosis, the frequency of
cavitary lung lesions is directly proportional to the number of the
number of peripheral blood CD4 T cells at the time of TB
diagnosis [2,6]. Furthermore, one study has revealed that distinct
functional subsets of CD4 effector T cells may predominate at the
site of infection in patients with cavitary and non-cavitary
pulmonary TB: Th1 cells were more common in bronchial lavage
of patients with non-cavitary TB, while Th2 cells were more
abundant in patients with cavitary TB [7]. In contrast, another
study found that lavage fluid of cavitary TB lesions contained a
predominance of neutrophils [8], which is consistent with several
potential mechanisms, including a dominant Th17 response [9].
Finally, recent studies in mice infected with M. tuberculosis have
revealed that dysregulation of CD4 T cell responses causes severe
lung inflammation and contributes to mortality [9,10]. In
particular, excessive IL-17 secretion has been found to be
associated with severe lung inflammation [9].
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During primary immune responses, naı¨ve CD4 T cells can
differentiate into Th1, Th2, or Th17 effector cells, or into
regulatory (Treg) cells; this is driven by distinct cytokines present
during proliferation and differentiation of antigen-activated T cells
[11,12]. These subsets of T helper cells have distinct functions. In
particular, IFN-c is the signature cytokine of Th1 cells, and can
activate mycobactericidal mechanisms in macrophages and restrict
progressive growth and dissemination of M. tuberculosis infection.
IFN-c also has potent immunoregulatory effects that attenuated
other T cell responses [9] and that regulate neutrophil-mediated
inflammation [13]. IL-17, produced by Th17 cells, is a potent pro-
inflammatory cytokine, as it induces expression of G-CSF,
resulting in increased production of neutrophils and induces
expression of selected neutrophil chemokines. Although IL-17 has
been shown to have beneficial effects in mice during early infection
with M. tuberculosis [14,15], excessive IL-17 responses are
detrimental to mice infected with M. tuberculosis [9,16]. In addition
to being produced by Th17 cells, IL-17 can be produced by other
cells, including cd T cells [17], which may play a role in control of
M. tuberculosis infection through the induction and formation of
mature granulomas [13]. In humans infected with M. tuberculosis,
IL-17 is expressed by antigen-specific CD4+ T cells, a subset of
these may also express other cytokines, including IFN-c, TNF,
and/or IL-2 [18]. Th1 and Th17 responses can cross-regulate
each other during M. tuberculosis infection; this may be important
for limiting immunopathologic consequences of infection
[9,19,20].
In light of evidence that CD4 T cells may contribute to both
control of M. tuberculosis as well as to the immunopathology that
contributes to morbidity and mortality in TB, there is considerable
interest in identifying differential CD4 T cell responses that are
associated with beneficial and detrimental outcomes. The present
study was designed to test the overall hypothesis that humans
infected with M. tuberculosis or vaccinated with M. bovis BCG
generate a range of Th1 and Th17 responses to M. tuberculosis
antigens. As an initial test of this hypothesis, we quantitated
interferon gamma (IFN-c) and IL-17 secretion after stimulation
with selected M. tuberculosis antigens by PBMC from tuberculin
skin test-reactive (TST+) healthy individuals. We were especially
interested in determining the intersubject variation in the
relationship between the quantity of IFN-c and IL-17 released
in response to M. tuberculosis antigens.
Results
Characteristics of subjects
Twenty one tuberculin skin test positive ($5 mm induration;
TST+) healthy adults in New York City gave informed consent
and donated venous blood for this study. The subjects ranged in
age from 21 to 62 years old (mean 34.1 years), and were diverse in
their countries of birth, which included Turkey, Peru, Pakistan,
South Korea, Vietnam, Nigeria, Russia, China, Brazil, Albania,
Uraguay, Jamaica, the Philippines, and the USA. Four of the
subjects (donors 14, 17, 20, and 40) had been treated previously for
latent TB infection; seven (donors 16, 24, 26, 31, 32, 36, and 40)
reported having been vaccinated with BCG. Three (donors 15, 36,
and 40) had .5 but ,10 mm induration in response to
intradermal PPD. None of the subjects had a history of active
tuberculosis, and none had evidence of HIV infection.
Variation in IFN-c responses
Since IFN-c has been widely studied, and since it is essential for
control of tuberculosis in mice and in humans, we examined its
secretion in response to selected stimuli. As shown in Figure 1A
and Table 1, there was a large intersubject range in the amounts of
IFN-c secreted in response to the mycobacterial antigens Purified
Protein Derivative (PPD), ESAT-6, and Ag85B, as well as with
whole, live, Mycobacterium bovis BCG. For example, PPD stimulated
IFN-c secretion in all 21 subjects, but the amounts varied between
individuals over a 500-fold range, from 128 to 64,569 pg/ml
(Figure 1A and Table 1). Likewise, IFN-c responses to Ag85B were
detectable in 19 of 21 subjects and varied over a 1,525-fold range,
from 28.1 to 42,879 pg/ml. ESAT-6 stimulated detectable
quantities of IFN-c in 14 of 21 subjects, consistent with our
inclusion of subjects with a history of BCG vaccination. In the 14
subjects that responded to ESAT-6, IFN-c secretion varied over an
even wider, 4,352-fold range, from 12.9 to 56,147 pg/ml. It is
notable that among the donors, the largest quantities of IFN-c
secreted in response to PPD, Ag85B, ESAT-6, and live BCG all
occurred in the same subject (donor 12, Table 1), although the
lowest IFN-c responses to these stimuli occurred in 4 different
subjects (donors 11, 26, 16, and 23, respectively; Table 1).
Notably, despite the heterogeneity of the subjects with respect to
their BCG vaccination status or treatment for latent TB infection,
the responses of individuals in these specific groups did not
account for either the highest or the lowest responses to any of the
stimuli, with the exception that cells from 4 of the 7 subjects with a
history of BCG vaccination did not respond to stimulation with
ESAT-6.
To determine whether the wide range of intersubject variation
in IFN-c secretion simply reflected variation of the number of
viable T cells in the individual PBMC samples and/or a general
property of the T cells in the individual subjects, we examined
IFN-c secretion in response to the polyclonal T cell stimulus,
phytohemagglutinin (PHA). This also revealed a range of IFN-c
responses. However, the variation was less than for any of the
mycobacterial antigens, varying only 70-fold (from 782 to
55,626 pg/ml) in the 21 subjects. Moreover, the subjects whose
cells secreted the largest quantities of IFN-c in response to PHA
were not the same as those with the largest responses to
mycobacterial antigens. These results indicate a very large
variation in intersubject responses to M. tuberculosis antigens, and
that the variation is much wider than to a polyclonal T cell
stimulus.
Variation in IL-17 responses
To further determine the extent to which T lymphocytes in
individual TST+ subjects vary in their responses to mycobacterial
antigens, we assayed interleukin-17A (IL-17) secretion in response
to the same stimuli as used for IFN-c responses. This also revealed
a range of individual responses, varying 46-, 35-, 68.5-, and 39-
fold, to PPD, Ag85B, ESAT-6, and live BCG, respectively
(Figure 1B and Table 1). By comparison, individual IL-17
responses to PHA varied over a narrower, 20.5-fold range. It is
also noteworthy that the individuals whose IFN-c responses
represented the high and low extremes in response to the selected
mycobacterial antigens were not the same as those with the
extremes of IL-17 responses (Table 1). When responses to PPD
were analyzed for the 21 donors, there was no correlation between
IFN-c and IL-17 responses (Spearman r value, 0.055; p = 0.81).
Comparison of IFN-c and IL-17 responses within and
between donors
The separate analyses of IFN-c and IL-17 responses indicated
considerable variation between individuals for secretion of these
two cytokines in response to M. tuberculosis antigens, and suggested
that the two responses were not fully concordant. Therefore, we
examined the range of variation in the ratio of the amounts of
TB Immune Response Variation
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IFN-c and IL-17. This also revealed considerable intersubject
variation, with ratios of IFN-c/IL-17 secretion varying 441- ,
1,412- , 1,658- and 127-fold for PPD, Ag85B, ESAT-6, and BCG,
respectively (Figure 1C and Table 1). Consistent with the smaller
variation in IFN-c and IL-17 responses to PHA compared to
responses to mycobacterial antigens, the ratios of IFN-c/IL-17
varied over a 100-fold range (Figure 1C and Table 1).
Examination of the ratios of IFN-c/IL-17 in response to
individual antigens revealed that 3 subjects (donors 12, 23, and 33;
Table 1) exhibited the highest ratios to all 3 of the soluble M.
tuberculosis antigens (PPD, Ag85B, and ESAT-6). Two of these
(subjects 12 and 23) also exhibited the highest ratios in response to
PHA, while the ratio of subject 33 ranked seventh among the
subjects in response to PHA. The heterogeneity in donors with
Figure 1. Variation of IFN-c and IL-17 responses to mycobacterial antigens. PBMC were incubated with the indicated stimuli for 24 h (for
IFN-c responses) or 72 h (for IL-17 responses); cytokine secretion was assayed by ELISA. (A) IFN-c secretion in response to PHA, PPD, ESAT-6, Ag85B, or
live M. bovis BCG. Each symbol reflects responses of a single subject whose responses were assayed in triplicate. The horizontal bar indicates the
mean value for the group. (B) IL-17 secretion in response to PHA, PPD, ESAT-6, Ag85B, or live M. bovis BCG. Each symbol reflects responses of a single
subject whose responses were assayed in triplicate. The horizontal bar indicates the mean value for the group. (C) Ratio of IFN-c to IL-17 secretion in
response to the stimuli in panels A and B. Ratios were calculated using the mean value for IFN-c and for IL-17 for each subject; the horizontal bar
indicates the mean value for the group of subjects.
doi:10.1371/journal.pone.0042716.g001
Table 1. IFN-c and IL-17 responses in healthy TST-positive donors.
Subject
Unstimulated
control PHA PPD ESAT-6 Ag85B BCG
IFNc IL17 Ratio IFNc IL17 Ratio IFNc IL17 Ratio IFNc IL17 Ratio IFNc IL17 Ratio IFNc IL17 Ratio
2 320 15.3 21.2 26930 217.1 125.5 959.5 129.3 8.6 1602.6 8.3 219.5 3109 117 27.9 9942.7 5.9 2105.3
7 0 3.3 0 25951.4 262.4 98.7 5873.3 93.7 65.9 3426.0 157.7 23. 8 0 76.5 0 2661.5 14.7 193.2
11 2.04 0 NV 782.0 66.6 13.1 128.2 36.2 3.7 0 0 NV 1.6 15.4 0.21 378.2 0.99 0
12 16.4 1.2 14.2 30910 174.6 176.4 64569 54.9 1344.9 56147 35.3 1990.5 42879 44.7 989.2 67865 193.3 415.6
14 0 0.09 31.2 18020 387.4 46.9 1502.2 395.3 3.8 0.68 69.2 0.03 381.4 209.9 1.9
15 0 0.5 0 6686.9 484.1 13.8 3478.4 13.5 256.6 854.7 144.0 5.9 797.2 225.9 3.8
16 0 2.8 0 2255.3 171.8 13.3 1303.9 17.3 97.9 0 2.4 0 28.1 11.2 2.8
17 0 2.8 0 6343.4 90.3 71.9 1054.9 22.1 48.9 0 2.8 0 145.4 15.5 9.8
19 0 5.0 0 55626 232.6 240.9 2744.8 101.9 27.8 0 12.9 0 1190 96.5 13.0
20 0 6.2 0 10338 464.9 22.9 4205.7 114.6 35.3 333.7 42.6 8.4 47.7 32.7 2.1
22 0 1.4 0 11672 291.2 40.4 437.9 8.5 53.6 2.1 5.6 0.53 72.4 22.6 3.311
23 0 2.2 0 17512 108.5 161.2 9322.4 9.3 997.4 2700.4 7.3 387.4 787.1 6.4 136.2 130 4.9 23.5
24 0 1.7 0 10300 196.9 53.8 400.8 104.4 3.1 0 16.1 0 531.9 126.5 6.6 1566.3 72.6 30.4
26 0 3.56 0 24183 581.1 41.7 13017 72.6 189.8 12.9 12.8 1.2 853.8 81.8 11.2 361.8 19.1 16.6
27 0 2.75 0 32359 295.2 110.8 17800 67.0 277.4 594.7 48.4 13.5 171.3 36.2 5.6 2224.6 61.6 34.9
31 98.1 1.3 83.1 15955 681.7 32.166 3816.0 84.3 40.1 57.7 2.3 27.2 199.3 46.8 4.9 964.7 11.4 119.8
32 15.8 13.9 1.2 35153 1363.4 32.3 5103 45.2 109.4 17.7 6.4 3.6 373.8 14.7 26.4 458.5 18.2 37.2
33 290.8 18.6 83.2 33582 419.1 81.6 27342.7 20.1 1367.5 15772.3 12.9 1227.9 3099 18.6 167.8 10383 16.6 635.8
36 0 4.7 0 5623.3 303.8 18.6 241.8 61.6 3.9 0 6.3 0 40.8 77.8 0.7 361.3 10.2 48.4
38 0 1.5 0 19954 406.9 49.7 30998 167.3 190.3 22702 129.1 200.9 44.4 38.0 1.1 21422 92.3 244.80
40 15.6 4.2 3.2 2311 946.7 2.4 3530 80.4 43.1 203.8 24.9 8.3 85.8 19.9 4.6 676.6 6.1 118.5
IFNc and IL-17 values are expressed in pg/ml. Ratio indicates IFN-c/IL-17. NV =No value; not calculated due response of IFN-c or IL-17 below the limit of detection.
doi:10.1371/journal.pone.0042716.t001
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respect to BCG vaccination status or history of treatment for latent
TB infection did not account for these extremes, as the responses
in these individuals were in the intermediate range for the entire
group of donors.
The analysis of intersubject variation of IFN-c , IL-17, and the
ratio of IFN-c/IL-17 suggested that, while the results for most of
the subjects clustered in a narrow range, the results for several of
the subjects were outside of this range, and exceeded it by a
considerable amount (Table 2). To determine whether the three
subjects with the highest ratios of IFN-c/IL-17 represent true
extremes, we examined them using previously-described criteria
[21]. This revealed that when responses to PPD or Ag85B were
considered, all three subjects met the criteria for extreme responses
(Table 3). The ratios of two of the subjects met the criteria for
extreme responses to ESAT-6, and one of the three met the
criteria when BCG was used as the stimulus.
Stimulus-by-stimulus comparison of IFN-c/IL-17
responses
In addition to the variation in IFN-c and IL-17 responses by the
cells of individual subjects, we also noted a range of IFN-c and IL-
17 ratios in response to individual mycobacterial stimuli. For the
crude antigen mixtures represented by PPD and live M. bovis BCG,
the median IFN-c/IL-17 ratios varied over approximately a 2-fold
range (54–118; Table 2), while for the two purified protein
antigens, Ag85B and ESAT-6, the median ratios varied nearly 4-
fold (6.6–24.0; Table 2). These results suggest that individual M.
tuberculosis antigens may induce qualitatively distinct T cell
responses, perhaps due in part to the differences in expression
patterns of the genes encoding these antigens [22].
Discussion
The aim of this study was to quantitate the variation of IFN-c/
IL-17 in response to M. tuberculosis-specific antigens in healthy
TST+ adults. We found extensive variation in the quantities of
IFN-c and IL-17 secreted in response to PPD, Ag85B, ESAT-6,
and live M. bovis BCG. We also found that the variation in IFN-c
and IL-17 responses to mycobacterial antigens was greater than
that to the polyclonal T cell stimulus, PHA, indicating that the
variation in intersubject responses was not a general property of T
cell responses of the individual subjects.
While this study revealed wide variation in IFN-c and IL-17
responses to PPD, Ag85B, ESAT-6, and live BCG in a group of
subjects, it also revealed that a subset of subjects exhibits extreme
responses, reflected by secretion of large quantities of IFN-c, and
high ratios of IFN-c/IL-17 secretion. This is particularly
remarkable, since all of the subjects were healthy at the time of
the analysis, supporting the model that latent TB infection
represents a spectrum of host and bacterial interactions [23].
Additional longitudinal analyses that consider multiple T cell
responses to multiple mycobacterial antigens and correlate them
with the outcomes of infection (that is, prolonged latent TB
infection, or progression to active TB disease) may provide insight
into the adaptive immune responses that provide durable control
of M. tuberculosis, especially if they take into account the effects of
variations in the infecting bacteria and in the genetic backgrounds
of the human subjects involved [24]. Furthermore, the temporal
characteristics of bacterial antigen gene expression during the
course of infection may contribute to variations in the T cell
responses to individual antigens [22,25,26]. For example, antigens
expressed at different times after infection may occupy dendritic
cells in distinct inflammatory environments that cause them to
drive differentiation of the responding antigen-specific T cells
toward Th1 or Th17 pathways.
Since human CD4 T cells are implicated in immunopathology
as well as in protective immunity in tuberculosis, identification of
correlates of CD4 T cell-mediated immunity, and the design of
improved TB vaccines, is proving to be a challenge. In particular,
the number of peripheral blood CD4 T cells at the time of TB
diagnosis in HIV-TB coinfected individuals correlates closely with
the likelihood that a patient will have cavitary tuberculosis [2].
Although the pathogenesis of the lung tissue damage that underlies
cavitary TB is poorly understood, it appears that CD4 T cells
contribute, directly or indirectly. Since cavitary TB causes
significantly more secondary cases than does non-cavitary TB
(reviewed in [2]), characterization of the antigen specificity and
effector functions of CD4 T cells in persons that progress from
latent TB to cavitary or noncavitary TB can have considerable
public health importance, as identification and treatment of those
at highest risk may provide a cost-effective approach to decreasing
TB transmission. Our finding that healthy TST+ individuals
exhibit wide variation in the amounts of IFN-c and IL-17 secreted
in response to mycobacterial antigens suggests that analysis of
multiple T cell effector functions in response to mycobacterial
antigens may reveal correlates of specific outcomes of M.
tuberculosis infection. Such studies should also take into account
the potential impact of infection with distinct strains of M.
tuberculosis, especially in individuals of distinct genetic backgrounds
[24]. The results reported here also suggest that analysis of subjects
with extreme responses might be especially valuable in revealing
correlates of protective immunity and immunopathology.
The present study has several limitations. First, as a pilot study
in healthy individuals, it does not provide the opportunity to
compare specific T cell responses with clinical or pathological
outcomes. Nevertheless, it provides data on the spectrum and
extent of variation of IFN-c and IL-17 responses to serve as the
basis for further studies of subjects with other clinical phenotypes.
Further studies are needed to extend the present findings, to
determine whether the wide donor-to-donor variation in cytokine
secretion observed in this study represent differences in the
number of responding cells, the amount of cytokine synthesized
per cell, or both. Second, even though all of our subjects were
healthy adults, they included subjects that had received BCG
vaccine, and they consisted of ethnically-diverse individuals that
are likely to be latently infected with M. tuberculosis strains from
distinct genetic lineages [27]. Moreover, they may also vary in the
duration between their initial infection with M. tuberculosis and/or
BCG vaccination and the time of their blood donation. Although
the natural history of antigen-specific T cell responses to
mycobacterial antigens has not been characterized in detail
outside the context of vaccine trials, this is a variable that may
have contributed to our findings.
Table 2. Descriptive Statistics of IFN-c/IL-17 ratios.
Stimulus: PHA PPD ESAT-6 Ag85B BCG
Number of subjects
studied per stimulus:
21 21 13 19 13
Minimum 2.400 3.100 1.200 0.7000 16.60
25%ile 21.00 18.30 7.150 3.300 32.50
Median 47.00 54.00 24.00 6.600 118.0
75%ile 105.0 223.5 303.5 28.00 330.5
Maximum 241.0 1367 1990 1865 2105
doi:10.1371/journal.pone.0042716.t002
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In conclusion, this study provides evidence for a wide range of
IFN-c and IL-17 responses to M.tuberculosis specific antigens in
TST+ adults, and indicates that in a population certain individuals
exhibit extreme T cell responses to mycobacterial antigens. We
anticipate that these findings will be valuable in characterizing T
cell responses to M. tuberculosis antigens in other contexts, and will
provide the basis for expanded studies to identify correlates of
protective and pathologic immune responses in human tubercu-
losis.
Methods
Human subjects
During a 4 month period, healthy healthcare and research
workers at the New York University Medical Center were
screened by tuberculin skin testing and offered enrollment in this
study if they responded with$5 mm induration 48–72 hours after
intradermal injection of 5 TU of PPD. None of the subjects were
taking a regularly prescribed medication such as steroids or
immunosuppressive agents; individuals with HIV infection were
excluded from the present study. All of the the subjects were .18
years of age and provided written informed consent. Information
on BCG vaccination status was requested but was not confirmed
by independent means; IGRA testing was not routinely available
at our medical center during the period of this study. Written
informed consent was obtained from all subjects, and all
procedures were performed in accord with a protocol approved
by the New York University Medical Center Institutional Review
Board.
Isolation and stimulation of PBMC
Venous blood samples (30 ml) were collected in heparin tubes;
peripheral blood mononuclear cells (PBMC) were isolated within
3 hours after blood collection. PBMC isolation was performed by
density gradient centrifugation using Ficoll-Hypaque (Sigma-
Aldrich Histopaque-1077) following the manufacturer’s instruc-
tions. After washing the cells, 36105 cells per well were cultured in
200 mL of RPMI-1640 (GIBCO, Invitrogen) with 10% heat
inactivated pooled human AB serum, penicillin (50 U/ml),
streptomycin (50 mg/ml), 2 mM L-glutamine and 10 mM HEPES
using 96-well round-bottom plates (Costar). PBMC were then
stimulated with PHA (5 mg/ml), BCG (nominal MOI 1:1), PPD
(purified protein derivative, 10 mg/ml, Statens Serum Institute
Demark), native M. tuberculosis Ag85B (5 mg/ml, BEI Resource,
USA), recombinant ESAT-6 (5 mg/ml, Statens Serum Institue,
Demark), or medium alone as a negative control.
Cytokine analyses in culture supernatants by ELISA
Cells were cultured and stimulated with the aforementioned
antigens and controls for 24 hours (for IFN-c responses) or
72 hours (for IL-17 responses) at 37uC with 5% CO2. Superna-
tants were collected and stored at 270uC until the time of assay.
The concentration of IFN-c was determined using the Human
IFN-c ELISA Set (BD Biosciences, San Diego, CA,USA), after
diluting the supernatants sufficiently to yield results within the
linear range of the assay (routine dilutions were: PHA-stimulated
samples, 1:200; BCG 1:20; PPD, 1:10–1:50 and Ag85B stimulated
samples at 1:2) Supernatants from negative controls or ESAT-6
stimulated samples were not diluted, except for some samples that
contained high concentrations of IFN-c after ESAT-6 or Ag85B
stimulation, which were reassayed after dilution from 1:10–1:200.
IL-17 concentrations in supernatants were quantitated using the
Human IL-17 ELISA Set (eBioscience, USA) in supernatant after
72 hours incubation. Supernatants from PHA-stimulated samples
were diluted 1:2; all other assays were performed on undiluted
supernatants. All assays were done in triplicate. Plates were read at
450 nm within 30 minutes of the end of the assay, using an ELISA
plate reader.
Statistical analyses
Descriptive statistics were obtained, and Spearman correlation
was determined using Prism 4 for the Macintosh (GraphPad
Software, USA). Determination of extreme values was performed
as described in [21], and is detailed in the legend for Table 3.
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